PL3135286T3 - Sposoby zastosowania pochodnych amidów cyklicznych do leczenia schizofrenii i jej objawów - Google Patents

Sposoby zastosowania pochodnych amidów cyklicznych do leczenia schizofrenii i jej objawów

Info

Publication number
PL3135286T3
PL3135286T3 PL16181339.9T PL16181339T PL3135286T3 PL 3135286 T3 PL3135286 T3 PL 3135286T3 PL 16181339 T PL16181339 T PL 16181339T PL 3135286 T3 PL3135286 T3 PL 3135286T3
Authority
PL
Poland
Prior art keywords
symptoms
methods
amide derivatives
cyclic amide
treat schizophrenia
Prior art date
Application number
PL16181339.9T
Other languages
English (en)
Polish (pl)
Inventor
Remy Henri Luthringer
Lorenzo Pellegrini
Argeris Karabelas
Original Assignee
Minerva Neurosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Neurosciences, Inc. filed Critical Minerva Neurosciences, Inc.
Publication of PL3135286T3 publication Critical patent/PL3135286T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/0001Arrangements for dividing the transmission path
    • H04L5/0003Two-dimensional division
    • H04L5/0005Time-frequency
    • H04L5/0007Time-frequency the frequencies being orthogonal, e.g. OFDM(A) or DMT
    • H04L5/001Time-frequency the frequencies being orthogonal, e.g. OFDM(A) or DMT the frequencies being arranged in component carriers
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/0001Arrangements for dividing the transmission path
    • H04L5/0014Three-dimensional division
    • H04L5/0016Time-frequency-code
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/0001Arrangements for dividing the transmission path
    • H04L5/0014Three-dimensional division
    • H04L5/0016Time-frequency-code
    • H04L5/0019Time-frequency-code in which one code is applied, as a temporal sequence, to all frequencies
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/003Arrangements for allocating sub-channels of the transmission path
    • H04L5/0048Allocation of pilot signals, i.e. of signals known to the receiver
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/003Arrangements for allocating sub-channels of the transmission path
    • H04L5/0048Allocation of pilot signals, i.e. of signals known to the receiver
    • H04L5/005Allocation of pilot signals, i.e. of signals known to the receiver of common pilots, i.e. pilots destined for multiple users or terminals
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04LTRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00Arrangements affording multiple use of the transmission path
    • H04L5/003Arrangements for allocating sub-channels of the transmission path
    • H04L5/0053Allocation of signalling, i.e. of overhead other than pilot signals
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04WWIRELESS COMMUNICATION NETWORKS
    • H04W4/00Services specially adapted for wireless communication networks; Facilities therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Signal Processing (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL16181339.9T 2010-07-20 2011-07-20 Sposoby zastosowania pochodnych amidów cyklicznych do leczenia schizofrenii i jej objawów PL3135286T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36607510P 2010-07-20 2010-07-20

Publications (1)

Publication Number Publication Date
PL3135286T3 true PL3135286T3 (pl) 2024-04-22

Family

ID=45497166

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16181339.9T PL3135286T3 (pl) 2010-07-20 2011-07-20 Sposoby zastosowania pochodnych amidów cyklicznych do leczenia schizofrenii i jej objawów
PL11810349T PL2595484T3 (pl) 2010-07-20 2011-07-20 Zastosowanie cyklicznych pochodnych amidowych do leczenia zaburzeń snu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL11810349T PL2595484T3 (pl) 2010-07-20 2011-07-20 Zastosowanie cyklicznych pochodnych amidowych do leczenia zaburzeń snu

Country Status (22)

Country Link
US (3) US20180155318A1 (enExample)
EP (4) EP4494704A3 (enExample)
JP (2) JP6053678B2 (enExample)
KR (1) KR101867633B1 (enExample)
CN (1) CN103220910B (enExample)
BR (1) BR112013001303A2 (enExample)
CA (2) CA3117855C (enExample)
DK (2) DK3135286T3 (enExample)
ES (2) ES2656313T3 (enExample)
FI (1) FI3135286T3 (enExample)
HR (1) HRP20231446T1 (enExample)
HU (1) HUE064157T2 (enExample)
LT (1) LT3135286T (enExample)
NO (1) NO2595484T3 (enExample)
PL (2) PL3135286T3 (enExample)
PT (2) PT3135286T (enExample)
RS (1) RS64819B1 (enExample)
RU (1) RU2576611C2 (enExample)
SI (1) SI3135286T1 (enExample)
SM (1) SMT202300413T1 (enExample)
TW (1) TWI583679B (enExample)
WO (1) WO2012012542A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE058212T2 (hu) * 2014-12-02 2022-07-28 Minerva Neurosciences Inc 2-((1-(2(4-fluorfenil)-2-oxoetil)piperidin-4-il)metil)izoindolin-1-ont tartalmazó készítmények skizofrénia kezelésére
CN113908156A (zh) * 2016-05-25 2022-01-11 田边三菱制药株式会社 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
IL308650B2 (en) 2017-06-21 2025-08-01 Minerva Neurosciences Inc Gastro-resistant controlled release oral dosage forms
MY198713A (en) 2017-10-10 2023-09-19 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
EP3840835A1 (en) * 2018-08-21 2021-06-30 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3888340T2 (de) * 1988-01-21 1994-06-30 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
NZ235841A (en) * 1989-10-27 1993-03-26 Du Pont (n-phthalimidoalkyl) piperidine derivatives and pharmaceutical compositions
CA2069318A1 (en) * 1989-10-27 1991-04-28 Engelbert Ciganek (n-phthalimidoalkyl) piperidines
AU2001234175B2 (en) * 2000-02-29 2004-10-07 Mitsubishi Pharma Corporation Novel cyclic amide derivatives
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
AU2006256583B2 (en) * 2005-06-06 2012-01-12 Merck Sharp & Dohme Limited Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia
TW200817400A (en) * 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them

Also Published As

Publication number Publication date
US20180155318A1 (en) 2018-06-07
EP2595484A4 (en) 2014-04-23
US20220274951A1 (en) 2022-09-01
EP3135286B1 (en) 2023-09-06
SI3135286T1 (sl) 2024-02-29
BR112013001303A2 (pt) 2016-05-17
CA3117855C (en) 2023-01-10
RS64819B1 (sr) 2023-12-29
JP2017031159A (ja) 2017-02-09
RU2013107382A (ru) 2014-08-27
SMT202300413T1 (it) 2024-01-10
JP6200561B2 (ja) 2017-09-20
CN103220910A (zh) 2013-07-24
CA2806017A1 (en) 2012-01-26
JP6053678B2 (ja) 2016-12-27
EP4494704A3 (en) 2025-04-23
TWI583679B (zh) 2017-05-21
EP3135286A1 (en) 2017-03-01
EP2595484A1 (en) 2013-05-29
PL2595484T3 (pl) 2018-03-30
PT2595484T (pt) 2018-01-22
LT3135286T (lt) 2023-11-10
PT3135286T (pt) 2023-11-28
ES2656313T3 (es) 2018-02-26
TW201211021A (en) 2012-03-16
US20250179044A1 (en) 2025-06-05
HRP20231446T1 (hr) 2024-03-01
RU2576611C2 (ru) 2016-03-10
NO2595484T3 (enExample) 2018-03-17
KR101867633B1 (ko) 2018-06-15
ES2963362T3 (es) 2024-03-26
CA2806017C (en) 2021-06-29
EP3335731A1 (en) 2018-06-20
WO2012012542A1 (en) 2012-01-26
EP4494704A2 (en) 2025-01-22
JP2013531072A (ja) 2013-08-01
KR20130129905A (ko) 2013-11-29
CN103220910B (zh) 2016-05-11
HUE064157T2 (hu) 2024-02-28
DK2595484T3 (en) 2018-01-22
CA3117855A1 (en) 2012-01-26
FI3135286T3 (fi) 2023-11-15
EP3335731B1 (en) 2024-09-04
EP2595484B1 (en) 2017-10-18
DK3135286T3 (da) 2023-11-27

Similar Documents

Publication Publication Date Title
SG10202009963PA (en) Melanin modification compositions and methods of use
EP2539005A4 (en) ORAL PIECE AND METHODS OF USING THE SAME
EP2603202A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF TAUOPATHIES
ZA201308859B (en) Quinazolines as therapeutic compounds and related methods of use
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
IL227440A0 (en) Spherical support device and methods of use
EP2675471A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
IL221476A0 (en) Methods and compositions to treat hemorrhagic conditions of the brain
SI2523678T1 (sl) Antagonisti Wnt in postopki zdravljenja
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
EP2771030A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES
IL236830A0 (en) Diazahomoredene derivatives and methods of using them
GB201302653D0 (en) Pharmaceutical compositions and methods of treatment
ZA201405263B (en) Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof
PT2906221T (pt) Derivados de amida e ureia de aminoalquilpiperazinas e sua utilização
SI2827883T1 (sl) Inhibitorji TFPI in postopki uporabe
PL2767282T3 (pl) Zastosowanie glutarylohistaminy w leczeniu infekcji dróg oddechowych
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
IL256026B (en) Treatment methods
ZA201405265B (en) Derivatives of aza adamantane and uses thereof
SMT202300413T1 (it) Metodi di utilizzo di derivati di ammide ciclica per trattare schizofrenia e relativi sintomi
EP2672968A4 (en) ECONAZOL COMPOSITION AND TREATMENT PROCEDURE THEREWITH